A Cross‐Sectional Study of Prescribed Sleep Medication Use and Its Clinical and Demographic Factors Among Young People Receiving Mental Health Crisis Interventions in Sydney, Australia
Open Access
- 6 August 2026
- journal article
- research article
- Published by Wiley in Journal of Child and Adolescent Psychiatric Nursing
- Vol. 39 (3) , e70071
Abstract
Background: Clinical and demographic factors influencing prescribed sleep medication use in children and young people (CYP) have been studied inadequately. We aimed to examine the prevalence of prescribed sleep medication use among CYP experiencing mental health crises and its associations with clinical and demographic factors. Materials and Methods: Electronic medical records of CYP ( n = 201) attending the Macarthur Safeguards Acute Mental Health Crisis Service (referred to as the Safeguards Service) in Sydney, Australia, were reviewed. Descriptive statistics and bivariate and multivariate logistic regression analyses were performed. Multivariate logistic regression was used to estimate the Adjusted Odds Ratio (AOR) with 95% confidence intervals, examining the associations between prescribed sleep medication use and clinical and demographic factors. Results: The prevalence of prescribed sleep medication use (e.g., melatonin, benzodiazepines) among CYP was 20.9%. Multivariate regression analysis indicated that CYP's length of stay with the Safeguards Service was positively associated with increased prescribed sleep medication use (AOR = 3.61, 95% CI: 1.19–10.94, p = 0.023). CYP who were diagnosed with trauma‐related psychiatric conditions tended to use more prescribed sleep medication use (AOR = 2.81, 95% CI: 1.09–7.19, p < 0.032). Moreover, multiple medication prescriptions (polypharmacy) were strongly associated with increased prescription of SM (AOR = 11.36, 95% CI: 4.46–28.95, p < 0.000). Conclusion: Prescribed sleep medication use is significant in CYP experiencing mental health crises. This requires careful consideration due to potential risks, drug interactions, and limited evidence of long‐term benefits. There needs to be a focus on addressing the underlying causes of sleep difficulties and exploring adjunct non‐pharmacological interventions, especially for those with trauma‐related psychiatric conditions, those who tend to have a longer length of stay and are prescribed multiple medications, including for sleep.Keywords
This publication has 57 references indexed in Scilit:
- Sleep problems among Asian preschool children with neurodevelopmental disordersBrain and Development, 2024
- Prazosin Treatment of Sleep Problems in Youth with PTSDThe Brown University Child and Adolescent Behavior Letter, 2024
- The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessmenteClinicalMedicine, 2023
- Childhood sleep: physical, cognitive, and behavioral consequences and implicationsWorld Journal of Pediatrics, 2022
- Killing pain?: a population-based registry study of the use of prescription analgesics, anxiolytics, and hypnotics among all children, adolescents and young adults in Norway from 2004 to 2019European Child & Adolescent Psychiatry, 2022
- Long‐term benzodiazepines and z‐drug prescribing in Australian general practice between 2011 and 2018: A national studyPharmacology Research & Perspectives, 2021
- Pediatric use of prescribed melatonin in Sweden 2006–2017: a register based studyEuropean Child & Adolescent Psychiatry, 2020
- Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart ReviewNeurology and Therapy, 2017
- Insomnia in children and adolescents. A consensus documentAnales de Pediatría (English Edition), 2017
- World Medical Association Declaration of HelsinkiJAMA, 2013